Posts Tagged ‘Drug Delivery’
MC2 Biotek Group Offers Insights on PAD
MC2 Biotek Group’s Co-Founder and President Jesper J. Lange updated attendees on the company’s PAD technology, which may make existing drugs easier to use. The company’s lead product PADciclo is beginning Phase II testing against dry eye. MC2 Biotek has a collaboration with Moorfield Pharmaceuticals (part of Moorfield Eye Hospital) to develop a cyclosporine formulation…
Read MoreAllegro Gives Phase II News on Luminate
[creativ_media type=”vimeo” url=”https://vimeo.com/110730931″] Vicken Karageozian, MD, Co-Founder and CTO of Allegro Opthalmics LLC, updated the OIS audience on the clinical trial progress of Luminate, a first-in-class integrin peptide therapy that treats vitreo-retinal diseases by utilizing two mechanisms of action, anti-angiogenesis and vitreolysis. The company just initiated a Phase II study of the drug as a…
Read MoreOphthotech Shares Late-Stage Progress of Fovista
CEO David R. Guyer, MD reports that Phase III clinical trials of Ophthotech Corp.’s Fovista, a first-in-class anti-PDGF agent for wet AMD combination therapy, are on track. The company expects to receive top-line data in 2016. Meanwhile, Ophthotech is partnering with Novartis to sell Fovista outside the US. The deal could be worth $1 billion…
Read MoreMonoclonal Antibody Company XOMA Corp. Shares New Strategy
Monoclonal antibody company Xoma Corp. shared its new strategy of developing an internal pipeline of potential therapeutics. The company’s lead molecule is gevokizumab, a monoclonal antibody directed at the interleukin-1 beta, an important cytokine involved in multiple diseases where inflammation is a key component. Paul Rubin, MD, Senior Vice President, Research and Development and CMO,…
Read MoreNovaliq GmbH Using Semifluorinated Alkanes To Improve Solubility Of Topical Agents
Novaliq GmbH is using semifluorinated alkanes to improve solubility of topical agents like cyclosporin and latanoprost on the ocular surface, according to CEO Bernhard Günther. CyclASol and TacroSol compounds, which are ready for Phase II studies, pair with cyclosporine for dry eye and tacrolimus for uveitis, respectively, said Günther. Novaliq also has in development other…
Read MoreGrayBug With Preclinical Work On Microparticle Anti-VEGF Compound GB-102
GrayBug LLC is conducting preclinical work on its microparticle anti-VEGF compound GB-102, an extended-release injectable for wet AMD. The platform encapsulates the active drug ingredient in microparticles that degrade over time once injected into the eye to gradually release the agent. In mouse studies, GB-102 has been shown to prolong suppression of choroidal neovascularization 4.5…
Read MoreOcular Therapeutix
Amarpreet Sawhney, PhD, President and CEO of Ocular Therapeutix shared his company’s vision: to transform the treatment of eye diseases with sustained release therapeutics. Ocular’s ReSure Sealant, the first and only FDA approved ophthalmic sealant of its kind, is a synthetic, polyethylene glycol hydrogel used to seal corneal incisions following cataract surgery. The company’s most…
Read MoreAllysta Pharmaceuticals Developing Multi-Kinase Inhibitor To Treat Glaucoma
Aly1337 is a novel, small-molecule multi-kinase inhibitor that Allysta Pharmaceuticals Inc. is developing to treat glaucoma, said Henry Hsu, MD, Founder and CEO. Kinase, particularly Roh kinase, plays a key role in preventing aqueous outflow through the trabecular meshwork, thus contributing to increasing intraocular pressure. Among the kinases Aly1337 targets is kinase LRRK2, which, according…
Read MoreAerie Pharmaceuticals With Two ROCK Inhibitors In Development
Publicly traded Aerie Pharmaceuticals Inc. has two Rho kinase inhibitors, or ROCK inhibitors, in development, CEO Vicente Anido, Jr, PhD, reported Rhopressa which is in phase III studies, and Roclatan, a Rhopressa-latanoprost combination that is entering a Phase III trail. ROCK inhibitors have been known to improve aqueous outflow through the trabecular meshwork and, possibly, improve…
Read MoreONL Therapeutics Develops Novel Mechanism To Attack Fas Receptor Apoptosis
ONL Therapeutics Inc. is developing Met12, a small peptide inhibitor that uses a novel mechanism to attack Fas receptor apoptosis, which has a key role in retinal detachment and AMD, CEO John Freshley reported. The drug targets the pathway activated in Fas-mediated apoptosis, Freshley said. Fas is an antigen encoded to the tumor necrosis factor…
Read MoreKala Pharmaceuticals Offers Glimpse Into Preclinical Pipeline
Kala Pharmaceutical Inc. is moving its proprietary Lotoprednol Etaobnate Mucus Penetrating Particle (LE-MPP) platform through a host of trials, Interim President and CBO Charlie McDermott reported. Animal investigations showed that LE-MPP retained approximately 10 times the concentration of the agent on the ocular surface at one hour than either lotoprednol etabonate nanoparticle or suspension alone,…
Read MoreTranslatum Medicus Developing Option To Treat Dry AMD
Clinicians have few treatment options for dry AMD, but Translatum Medicus Inc., is working on an agent, TMi-018, for such an indication. President and CSO Shelley Boyd, MD, FRCSC, explained the company has reverse engineered an animal model to mimic the disease so investigators can test treatments. TMi-018 is a first-in-class transcriptional modulator that is…
Read More